In the Claims

1-10 (Cancelled)

11. (Currently Added) A transdermal therapeutic system comprising an active substance impermeable backing layer, at least one polymer layer with micro-reservoirs present therein, at least one active substance having moderate polarity, and a protective layer for removal before use, wherein

a) the polymer fraction of the polymer layer is at least 70% by weight, of polysiloxanes,

b) the microreservoirs are essentially free of water and contain the active substance in dissolved form,

c) the solvent for the active substance comprises at least 50% by weight, of an ambiphilic solvent, and

d) the ambiphilic solvent is soluble in polysiloxanes to the extent of not more than about 20%.

12. (Currently Added) The transdermal system as claimed in claim 11, wherein the polymer fraction is at least 80% by weight of a polysiloxane.

13. (Currently Added) The transdermal system as claimed in claim 11, wherein the solvent comprises at least 80% by weight of an ambiphilic solvent.

14. (Currently Added) The transdermal system as claimed in claim 11, wherein the ambiphilic solvent is a dipolar organic solvent.

15. (Currently Added) The transdermal therapeutic system as claimed in claim 11, wherein the polysiloxane is amine-resistant.

16. (Currently Added) The transdermal therapeutic system as claimed in claim 11, wherein the microreservoirs are essentially free from water.

17. (Currently Added) The transdermal therapeutic system as claimed in claim 11, wherein the polysiloxane is self-adhesive and optionally comprises at least one filler.

18. (Currently Added) The transdermal therapeutic system as claimed in claim 11, that further comprises at least one self-adhesive layer, which is microreservoir-free, for anchoring on the skin and/or for anchoring with the backing layer is adjacent to the polymer layer with microreservoirs.

19. (Currently Added) The transdermal therapeutic system as claimed in claim 11, wherein the ambiphilic solvent is liquid at room temperature, has a boiling point under standard conditions of more than 80°C, and is soluble to the extent of not more than 20% by weight in n-hexane or n-heptane.

20. (Currently Added) The transdermal therapeutic system as claimed in claim 19 wherein the ambiphilic solvent has a boiling point under standard conditions of more than 110°C.

21. (Currently Added) The transdermal therapeutic system as claimed in claim 19, wherein the ambiphilic solvent is selected from the group consisting of diethylene glycol monoethyl ether, diethylene glycol dimethyl ether, butanediol, tetrahydrofurfuryl alcohol, dipropylene glycol and a mixture thereof.

22. (Currently Added) The transdermal therapeutic system as claimed in claim 11, wherein the boiling point of the solvent is above that of the solvent for the polysiloxane, by at least 10°C.

23. (Currently Added) The transdermal therapeutic system as claimed in claim 22, wherein the boiling point of the solvent is at least 30°C above that of the solvent for the polysiloxane.

24. (Currently Added) The transdermal therapeutic system as claimed in claim 11, wherein the maximum size of the microreservoirs does not exceed 80% of the thickness of the polymer layer, and have an average diameter of 5 – 50 µm.

25. (Currently Added) The transdermal therapeutic system as claimed in claim 24, wherein the microreservoirs have an average diameter of 5 – 30 µm.

26. (Currently Added) The transdermal therapeutic system as claimed in claim 11, wherein the microreservoirs comprise, in addition to the active substance and the ambiphilic solvent, a crystallization inhibitor, a viscosity-increasing agent and/ or a pH regulator.

27. (Currently Added) A process for producing polysiloxane films charged with active substance microreservoirs, which comprises dissolving the active substance in an ambiphilic solvent comprising at least 50% by weight of dipolar organic solvents, dispersing this solution in a solution of a polysiloxane, coating the resulting dispersion onto an appropriate film, and removing the solvent of the polysiloxane at temperatures of between 25 and 100°C.

28. (Currently Added) A transdermal therapeutic system comprising an active substance impermeable backing layer, at least one polymer layer with micro-reservoirs present therein, at least one active substance having moderate polarity, and a protective layer for removal before use, wherein

a) the polymer fraction of the polymer layer is at least 70% by weight, of polysiloxanes,

b) the microreservoirs are essentially free of water and contain the active substance in dissolved form,

c) the solvent for the active substance comprises at least 50% by weight, of an ambiphilic solvent, and

d) the ambiphilic solvent is soluble in polysiloxane to the extent of not more than about 20% by weight and is miscible with water at least in a weight ratio of one part of solvent 3 parts to water.